It starts with the safety profile
SOLAR safety data: Drug-related adverse events through Month 12
- Defined as “treatment-related” as assessed by the investigator. Only maximum-graded report per adverse reaction contributes to table.
- Pyrexia: includes pyrexia, feeling hot, chills, influenza-like illness, body temperature increased.
- Fatigue: includes fatigue, malaise, asthenia.
- Musculoskeletal pain: includes musculoskeletal pain, musculoskeletal discomfort, back pain, myalgia, pain in extremity.
- Sleep disorders: includes insomnia, poor quality sleep, somnolence.
ISRs with CABENUVA during maintenance phase of SOLAR1,2*
*Participants’ injection schedule during the maintenance phase: oral lead-in—Month 1, 2, 4, 6, 8, 10, 12; Direct to injections—Day 1, Month 1, 3, 5, 7, 9, 11. Data for the 2 arms have been combined.2
Learn more about CABENUVA
References:
- Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):E566-E577. doi.org/10.1016/S2352-3018(23)00136-4
- Data on file. ViiV Healthcare group of companies. Durham, NC.
- ClinicalTrials.gov. SOLAR Study. Available at: https://clinicaltrials.gov/ct2/show/NCT04542070. Accessed February 16, 2023.
CBRWCNT230020